Abstract:Abstract Background Post-vaccination myopericarditis is reported after immunization with coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines. The effect of inadvertent intravenous injection of this vaccine on the heart is unknown. Methods We compared the clinical manifestations, histopathological changes, tissue mRNA expression, and serum levels of cytokine/chemokine and troponin in Balb/c mice at different time points after intravenous (IV) or intramuscular (IM) vaccine injection with normal saline (NS) control. Results Although significant weight loss and higher serum cytokine/chemokine levels were found in IM group at 1–2 days post-injection (dpi), only IV group developed histopathological changes of myopericarditis as evidenced by cardiomyocyte degeneration, apoptosis, and necrosis with adjacent inflammatory cell infiltration and calcific deposits on visceral pericardium, although evidence of coronary artery or other cardiac pathologies was absent. Serum troponin level was significantly higher in IV group. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antigen expression by immunostaining was occasionally found in infiltrating immune cells of the heart or injection site, in cardiomyocytes and intracardiac vascular endothelial cells, but not skeletal myocytes. The histological changes of myopericarditis after the first IV-priming dose persisted for 2 weeks and were markedly aggravated by a second IM- or IV-booster dose. Cardiac tissue mRNA expression of interleukin (IL)-1β, interferon (IFN)-β, IL-6, and tumor necrosis factor (TNF)-α increased significantly from 1 dpi to 2 dpi in the IV group but not the IM group, compatible with presence of myopericarditis in the IV group. Ballooning degeneration of hepatocytes was consistently found in the IV group. All other organs appeared normal. Conclusions This study provided in vivo evidence that inadvertent intravenous injection of COVID-19 mRNA vaccines may induce myopericarditis. Brief withdrawal of syringe plunger to exclude blood aspiration may be one possible way to reduce such risk.

Inadvertent subcutaneous injection of COVID-19 vaccine

Inadvertent injection of COVID-19 vaccine into deltoid muscle vasculature may result in vaccine distribution to distance tissues and consequent adverse reactions

Could inadvertent intravenous injection of COVID-19 vaccines cause severe adverse events?

Subcutaneous vaccine administration – an outmoded practice

Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model

COVID-19 vaccination: effective utilization of low dead space (LDS) syringes

Delivery systems for intradermal vaccination

Emerging adjuvants for intradermal vaccination

Microneedles: quick and easy delivery methods of vaccines

Subcutaneous administration of inactivated hepatitis B vaccine by automatic jet injection

A Promising Needle-Free Pyro-Drive Jet Injector for Augmentation of Immunity by Intradermal Injection as a Physical Adjuvant

Microneedles: An Emerging Vaccine Delivery Tool and a Prospective Solution to the Challenges of SARS-CoV-2 Mass Vaccination

Preclinical evaluation of performance, safety and usability of VAX-ID®, a novel intradermal injection device

Cutaneous immunization: an evolving paradigm in influenza vaccines.

Microneedle-Mediated Vaccination: Innovation and Translation.

Recurrent injection‐site reactions after incorrect subcutaneous administration of a COVID‐19 vaccine

Delivery of Experimental mRNA Vaccine Encoding the RBD of SARS-CoV-2 by Jet Injection

Microneedle technology for potential SARS-CoV-2 vaccine delivery

Improved DNA Vaccine Delivery with Needle-Free Injection Systems

A Needle-Free Jet Injection System for Controlled Release and Repeated Biopharmaceutical Delivery

Vaccine delivery systems and administration routes: Advanced biotechnological techniques to improve the immunization efficacy